Late Recurrence of Lupus Nephritis in a Renal Transplant Recipient: Response to Mycophenolate Mofetil

Clinically significant recurrence of lupus nephritis in the renal allograft is low, with an incidence of 1 to 3%, and usually occurs within the first 6years after transplantation. We report an unusual case of a patient with end-stage renal disease caused by lupus nephritis who received a kidney tran...

Full description

Saved in:
Bibliographic Details
Published in:The American journal of the medical sciences 2001-09, Vol.322 (3), p.166-169
Main Authors: Ahuja, Tejinder S., Boughton, Judy, Weiss, Vasanta, Memon, Amir, Remmers, August, Rajaraman, Srinivasan
Format: Article
Language:English
Subjects:
Adult
Biological and medical sciences
Female
Humans
Immunosuppressive Agents - therapeutic use
Kidney Transplantation - adverse effects
Kidney Transplantation - pathology
Lupus nephritis
Lupus Nephritis - drug therapy
Lupus Nephritis - etiology
Lupus Nephritis - pathology
Lupus Nephritis - surgery
Medical sciences
Mycophenolate mofetil
Mycophenolic Acid - analogs & derivatives
Mycophenolic Acid - therapeutic use
Nephrology. Urinary tract diseases
Nephropathies. Renovascular diseases. Renal failure
Recurrence
Renal allograft
Renal failure
Sarcoidosis. Granulomatous diseases of unproved etiology. Connective tissue diseases. Elastic tissue diseases. Vasculitis
Time Factors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Clinically significant recurrence of lupus nephritis in the renal allograft is low, with an incidence of 1 to 3%, and usually occurs within the first 6years after transplantation. We report an unusual case of a patient with end-stage renal disease caused by lupus nephritis who received a kidney transplant from a living relative; 13years later, the patient had a severe recurrence of diffuse proliferative lupus nephritis. The patient relapsed after receiving intravenous cyclophosphamide therapy and had a partial response to oral mycophenolate mofetil. In this report we review the risk factors for the recurrence of the systemic lupus erythematosus in the kidney graft and the anti-lupus activity of mycophenolate mofetil.
ISSN:0002-9629
1538-2990
DOI:10.1097/00000441-200109000-00012